MedPath

Effects of Hormonal Anabolic Deficiency and Neurovascular Alterations on Mortality in Male Patients With Heart Failure

Completed
Conditions
Heart Failure
Interventions
Diagnostic Test: Cardiopulmonary exercise test
Diagnostic Test: Muscle Sympathetic Nerve Activity
Diagnostic Test: Dual-energy X-ray absorptiometry
Diagnostic Test: Venous occlusion plethysmography
Diagnostic Test: Blood sample collection
Diagnostic Test: Dynamometers for Handgrip Strength
Registration Number
NCT03463226
Lead Sponsor
University of Sao Paulo General Hospital
Brief Summary

Heart failure (HF) has been associated with chronic deleterious effects on skeletal muscle, endocrine system, vasculature and sympathetic nervous system. These alterations have a significant impact on quality of life, leading to a reduction in functional capacity and limited symptoms, which involve dyspnea and fatigue. The investigators tested the hypothesis that hormonal anabolic deficiency associated with neurovascular alterations may worsen the prognosis of patients with heart failure.

Detailed Description

One hundred and fifty six patients have been enrolled so far. Methods were as described below:

* Muscle sympathetic nerve activity (MSNA) was directly recorded from the peroneal nerve using the microneurography technique ;

* All patients underwent symptom-limited cardiopulmonary exercise test performed on a cycle ergometer, using a ramp protocol with workload increments of 5 or 10 Watts per minute;

* Body composition measurements were performed using dual-energy X-ray absorptiometry (DXA);

* Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts;

* Blood samples were drawn in the morning after 12h overnight fasting. The laboratory tests included B-type natriuretic peptide (BNP; pg/mL) plasma level, serum sodium (mEq/L), serum potassium (mEq/L), creatinine (mg/dL), haemoglobin level (g/dL), high-sensitivity C-reactive protein (CRP; mg/L), lipid profile (triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein; mg/dL), and fasting glucose (mg/dL). Blood sample to assess hormone plasma levels were also drawn at the same time: total testosterone (TT), free testosterone (FT), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin-like growth factor 1 (IGF1).

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
169
Inclusion Criteria
  • age between 18 and 65 years old;
  • at least1 year of diagnosed HF;
  • left ventricular ejection fraction (LVEF) lower than 40% measured by echocardiography;
  • non-ischaemic and ischaemic aetiologies;
  • compensated HF with optimal medication for at least 3 months prior the study;
  • New York Heart Association (NYHA) class of I to IV.
Exclusion Criteria
  • patients with autonomic diabetic neuropathy;
  • patients with chronic renal failure with haemodialysis;
  • heart transplantation;
  • presence of pacemaker;
  • patients with muscular dystrophy (i.e. Duchenne muscular dystrophy);
  • patients submitted to any hormonal treatment;
  • history of cancer;
  • ongoing infection;
  • myocardial infarction with percutaneous coronary intervention or revascularization 6 months prior to the study entry.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Low testosteroneCardiopulmonary exercise testPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Low testosteroneMuscle Sympathetic Nerve ActivityPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Low testosteroneDynamometers for Handgrip StrengthPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneVenous occlusion plethysmographyPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Low testosteroneVenous occlusion plethysmographyPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneCardiopulmonary exercise testPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneDual-energy X-ray absorptiometryPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Low testosteroneBlood sample collectionPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneMuscle Sympathetic Nerve ActivityPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Low testosteroneDual-energy X-ray absorptiometryPatients with HF and testosterone deficiency. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneBlood sample collectionPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Normal testosteroneDynamometers for Handgrip StrengthPatients with HF and normal plasma levels of testosterone. * Cardiopulmonary exercise test * Muscle Sympathetic Nerve Activity * Dual-energy X-ray absorptiometry * Venous occlusion plethysmography * Blood sample collection * Dynamometers for Handgrip Strength
Primary Outcome Measures
NameTimeMethod
Impact of neurovascular alterations on mortality2 years

Venous occlusion pletysmography was used to evaluate vasodilation.

Impact of muscle sympathetic nerve activity on mortality2 years

Microneurography was used to assess the sympathetic nervous system.

Impact of testosterone deficiency on mortality2 years

Blood sample was collected in the morning (between 8:00-10:00 a.m.) after 12 hours fasting.

Secondary Outcome Measures
NameTimeMethod
Impact of testosterone deficiency on functional capacity2 years

All patients underwent symptom-limited cardiopulmonary exercise test to measure functional capacity.

Impact of testosterone deficiency on body composition2 years

Body composition measurements were performed using dual-energy X-ray absorptiometry.

Impact of testosterone deficiency on strength2 years

Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.

Trial Locations

Locations (1)

Instituto do Coração do Hospital da Clínicas da Universidade de Sao Paulo

🇧🇷

Sao Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath